Home » Topics » BioWorld Science

BioWorld Science
RSS

Foamix reports further data from third phase III trial of FMX-101 for moderate to severe acne

Oct. 2, 2018

Shanghai Institute of Materia Medica presents BRD4 inhibitors

Oct. 2, 2018

Guangzhou Maxinovel Pharmaceuticals patents adenosine A2A receptor antagonists

Oct. 2, 2018

Bromodomain-containing protein 4 inhibitors discovered at GlaxoSmithKline

Oct. 2, 2018

Shenzhen Targetrx Biotechnology synthesizes new VEGFR inhibitors

Oct. 2, 2018

A new model of persistent retinal neovascularization better reflects the human disease phenotype

Oct. 2, 2018

Novel humanized mouse model for idiopathic pulmonary fibrosis

Oct. 2, 2018

FDA approves Xyosted auto-injector for testosterone replacement

Oct. 2, 2018

Dragonfly Therapeutics and Merck & Co. establish cancer immunotherapy collaboration

Oct. 2, 2018

Omeros reports further phase II data on OMS-721 in IgA nephropathy

Oct. 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...